Piramal Pharma Limited (IN:PPLPHARMA)
:PPLPHARMA
Want to see IN:PPLPHARMA full AI Analyst Report?
PPLPHARMA Stock Chart & Stats
₹192.65
-₹4.80(-1.92%)
At close: 4:00 PM EST
₹192.65
-₹4.80(-1.92%)
Day’s Range― - ―
52-Week Range₹132.50 - ₹226.00
Previous CloseN/A
Volume1.66M
Average Volume (3M)264.14K
Market Cap
₹219.92B
Enterprise Value₹266.65B
Total Cash (Recent Filing)₹7.44B
Total Debt (Recent Filing)₹48.51B
Price to Earnings (P/E)―
Beta0.69
Next Earnings
May 27, 2026EPS Estimate
0.96Next Dividend Ex-DateN/A
Dividend Yield0.08%
Share Statistics
EPS (TTM)-0.70
Shares Outstanding1,329,248,200
10 Day Avg. Volume501,791
30 Day Avg. Volume264,138
Financial Highlights & Ratios
PEG Ratio0.84
Price to Book (P/B)3.72
Price to Sales (P/S)3.34
P/FCF Ratio132.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.2
Revenue Forecast (FY)₹102.13B
Bulls Say, Bears Say
Bulls Say
High Gross MarginsA gross margin near 64.7% reflects durable product and service mix advantages (specialty generics and CDMO work) that can absorb input cost swings and fund R&D or capacity expansion. High gross margins support long-term reinvestment and pricing flexibility if the mix is maintained.
Diversified Business ModelRevenue across CDMO, hospital generics, and OTC consumer healthcare reduces single-market dependence and creates multiple, structurally different cash flow sources: contracted CDMO projects, hospital tenders/volume sales, and retail OTC, improving resilience to sector-specific shocks over months to years.
Manageable LeverageA debt-to-equity around 0.60 indicates a balanced capital structure that limits refinancing strain and provides capacity for strategic investment or M&A. Manageable leverage reduces solvency risk and supports long-term operational planning, provided cash generation stabilizes.
Bears Say
Volatile Free Cash FlowSignificant FCF volatility undermines the company’s ability to consistently fund capex, service debt, or return capital. Even with stable operating cash flow metrics at times, erratic FCF hampers strategic investments and raises dependence on external financing for sustained growth over multiple quarters.
Inconsistent Net MarginsWide swings in net margins despite strong gross margins point to variable operating costs, one-off items, or pricing pressures. This inconsistency reduces predictability of earnings and ROE, complicating multi-quarter planning and weakening confidence in durable upward profitability trends.
Sharp Recent EPS And Revenue DeclineVery large negative EPS growth and steep reported revenue decline signal material near-term demand or profit disruptions. Such deep contractions can indicate execution, product lifecycle, or market-share issues that, if not reversed, impair long-term cash generation and the company’s ability to sustain investments.
Piramal Pharma Limited News
PPLPHARMA FAQ
What was Piramal Pharma Limited’s price range in the past 12 months?
Piramal Pharma Limited lowest stock price was ₹132.50 and its highest was ₹226.00 in the past 12 months.
What is Piramal Pharma Limited’s market cap?
Piramal Pharma Limited’s market cap is ₹219.92B.
When is Piramal Pharma Limited’s upcoming earnings report date?
Piramal Pharma Limited’s upcoming earnings report date is May 27, 2026 which is in 29 days.
How were Piramal Pharma Limited’s earnings last quarter?
Piramal Pharma Limited released its earnings results on Jan 28, 2026. The company reported -₹0.7 earnings per share for the quarter, missing the consensus estimate of -₹0.05 by -₹0.65.
Is Piramal Pharma Limited overvalued?
According to Wall Street analysts Piramal Pharma Limited’s price is currently Overvalued.
Does Piramal Pharma Limited pay dividends?
Piramal Pharma Limited pays a Notavailable dividend of ₹0.14 which represents an annual dividend yield of 0.08%. See more information on Piramal Pharma Limited dividends here
What is Piramal Pharma Limited’s EPS estimate?
Piramal Pharma Limited’s EPS estimate is 0.96.
How many shares outstanding does Piramal Pharma Limited have?
Piramal Pharma Limited has 1,329,248,200 shares outstanding.
What happened to Piramal Pharma Limited’s price movement after its last earnings report?
Piramal Pharma Limited reported an EPS of -₹0.7 in its last earnings report, missing expectations of -₹0.05. Following the earnings report the stock price went up 1.015%.
Which hedge fund is a major shareholder of Piramal Pharma Limited?
Currently, no hedge funds are holding shares in IN:PPLPHARMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Piramal Pharma Limited
Piramal Pharma Limited operates as a pharmaceutical company. It sells a portfolio of pharma products, as well as provides various pharma services, including injection, HPAPI, etc. The company was incorporated in 2020 and is based in Mumbai, India. Piramal Pharma Limited operates as a subsidiary of Piramal Enterprises Limited.
Technical Analysis
AstraZeneca Pharma India Limited
―
Gland Pharma Ltd.
―
IPCA Laboratories Limited
―
JB Chemicals & Pharmaceuticals Ltd.
―
PFIZER LIMITED
―